オプションチェーンは、TherapeuticsMDの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、TherapeuticsMDの市場センチメントを評価します。.

TherapeuticsMD (NASDAQ:TXMD) 株価情報, オプションチェーン

TherapeuticsMD

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

TherapeuticsMD Inc

TherapeuticsMD (TXMD) has provided an announcement. TherapeuticsMD, Inc., a Nevada-based company, has released its financial results for the first ...

TherapeuticsMD Releases Preliminary Q1 2024 Financials

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TherapeuticsMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/txmd-stock-quote/"><strong>TXMD</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>TherapeuticsMD reported earnings per share of -7 cents.</li><li>The company reported revenue of $313,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/txmd-stock-earnings-therapeuticsmd-for-q1-of-2024/">TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024

Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TherapeuticsMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/txmd-stock-quote/"><strong>TXMD</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>TherapeuticsMD reported earnings per share of -14 cents.</li><li>The company reported revenue of $502,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/06/txmd-stock-earnings-therapeuticsmd-for-q4-of-2023/">TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023

TherapeuticsMD (TXMD) has shared an update. TherapeuticsMD, Inc. recently disclosed its financial outcomes for the quarter ending June 30, 2024, th...

TherapeuticsMD Releases Preliminary Quarterly Financial Results

Therapeutics MD GAAP EPS of -$0.09

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TherapeuticsMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/txmd-stock-quote/"><strong>TXMD</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>TherapeuticsMD reported earnings per share of -9 cents.</li><li>The company reported revenue of $234,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/txmd-stock-earnings-therapeuticsmd-for-q2-of-2024/">TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024

An update from TherapeuticsMD ( ($TXMD) ) is now available. TherapeuticsMD, Inc. reported a reduced net loss for Q3 2024, with operating expenses a...

TherapeuticsMD Shifts Focus with Lower Q3 Losses

Therapeutics MD GAAP EPS of -$0.05

Therapeuticsmd Inc ( ($TXMD) ) has released its Q3 earnings. Here is a breakdown of the information Therapeuticsmd Inc presented to its investors. ...

Comments

TherapeuticsMD

TherapeuticsMD (TXMD) オプション

TherapeuticsMD (NASDAQ:TXMD) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル